Data as of Nov 4, 2026.
PCOV vs XSPI: Dividend Yield & Total Return
PCOV and XSPI both write options for income.
askIQ about this page
askIQ about PCOV and XSPI
Net assets: $10m on Nov 2, 2026 for Principal Equity Premium Income ETF, and $140m on Oct 28, 2026 for NEOS Boosted S&P 500 High Income ETF.
Not measured
PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
PCOV
−0.1%
Total return, distributions reinvested
Not measured
PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
PCOV
−0.1%
1.9% of it arrived as cash. Total return, distributions reinvested. PCOV since launch: paid 1.9%, price −2.0%, total −0.1%, not measured against a benchmark. Data to Nov 4, 2026.
Data to Nov 4, 2026.About even with SPY
XSPI since launch: paid 13.9%, price −2.3%, total +12.4%, SPY +12.1%, +0.3 pts. Data to Nov 4, 2026.
SPY
+12.1%
XSPI
+12.4%
13.9% of it arrived as cash
about even with SPY
Total return, distributions reinvested
About even with SPY
XSPI since launch: paid 13.9%, price −2.3%, total +12.4%, SPY +12.1%, +0.3 pts. Data to Nov 4, 2026.
SPY
+12.1%
XSPI
+12.4%
13.9% as cash
about even with SPY
13.9% of it arrived as cash. Both charts share one scale, with zero at the line. XSPI since launch: paid 13.9%, price −2.3%, total +12.4%, SPY +12.1%, +0.3 pts. Data to Nov 4, 2026.
Data to Nov 4, 2026.Pair scorecard
PCOV costs 0.64 points a year less; XSPI is 14.0 times larger.
Points (pts) are percentage points.
| Measure | PCOV | XSPI |
|---|---|---|
| Paid and earned | ||
| Price change | fell 2.0% (since Aug 19, 2026) | fell 2.3% (since Feb 3, 2026) |
| Return of capital, issuer estimate | 98% of the Oct 9, 2026 payment | |
| Against its benchmark | ||
| Benchmark | not published | S&P 500, measured through SPY |
| Cost and size | ||
| Expense ratio | 0.34% | 0.98% |
| Net assets, as of Oct 28, 2026 | $10m | $140m |
| Holdings | ||
| Holdings in common | not published | |
Side by side
As of Nov 4, 2026. Source: ETFIQ. Cash paid: distributions over the window, as a share of the starting price. Payout rate: the latest payment, annualized, over today’s price.
Window by window
| Total return | Cash paid | Against the benchmark | ||||
|---|---|---|---|---|---|---|
| Window | PCOV | XSPI | PCOV | XSPI | PCOV | XSPI |
| 3 months | – | +1.1% | – | 4.2% | – | +1.2 pts |
| 6 months | – | +7.0% | – | 8.5% | – | +2.0 pts |
| Since launchNot the same days: PCOV Aug 2026 · XSPI Feb 2026 | −0.1% | +12.4% | 1.9% | 13.9% | not measured | +0.3 pts |
– means no data for this window. Open this comparison in the app →
PCOV
Over the period from its first trade on Aug 19, 2026 to Nov 4, 2026, PCOV paid 1.9% of its starting value in cash distributions while its price fell 2.0%. With every distribution reinvested, the fund returned −0.1%. At its price on Nov 4, 2026 the latest distribution annualizes to 7.2%, paid periodically.
XSPI
Over the period from its first trade on Feb 3, 2026 to Nov 4, 2026, XSPI paid 13.9% of its starting value in cash distributions while its price fell 2.3%. With every distribution reinvested, the fund returned +12.4%. S&P 500 (SPY) returned +12.1% over the same days, so a holder was about even. At its price on Nov 4, 2026 the latest distribution annualizes to 16.6%, paid monthly. NEOS estimates that 98% of the distribution paid Oct 9, 2026 was a return of capital (its 19a-1 notice). That is a tax label, not a measure of erosion.
Questions people ask
Links are sources, not endorsements. A comparison is not a recommendation.
How this is computed
Every number is an ETFIQ calculation with distributions reinvested.
Cite this pageCitation, APA and Markdown
ETFIQ, PCOV against XSPI, data as of Nov 4, 2026. https://etfiq.com/compare/income/pcov-vs-xspi
ETFIQ. (Nov 4, 2026). PCOV against XSPI. Retrieved from https://etfiq.com/compare/income/pcov-vs-xspi
[PCOV against XSPI (ETFIQ, Nov 4, 2026)](https://etfiq.com/compare/income/pcov-vs-xspi)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.